SIMILAR PATTERNS OF AMINO ACIDS FOR 4MXX_B_DB8B601_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.65A	4mxxB-1k2pA: 24.9	4mxxB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 416 ALA A 428 LYS A 430 VAL A 458 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.81A	4mxxB-1k2pA: 24.9	4mxxB-1k2pA: 38.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 LYS A 222 VAL A 249 THR A 266 MET A 269 GLY A 272 LEU A 321	None	0.69A	4mxxB-1k9aA: 25.8	4mxxB-1k9aA: 30.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 VAL A 249 THR A 266 TYR A 268 MET A 269 GLY A 272 LEU A 321	None	0.53A	4mxxB-1k9aA: 25.8	4mxxB-1k9aA: 30.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	7	VAL A 588 ALA A 606 VAL A 638 TYR A 656 MET A 657 GLY A 660 LEU A 731	None	0.53A	4mxxB-1lufA: 32.1	4mxxB-1lufA: 32.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 267 VAL A 275 ALA A 288 LYS A 290 VAL A 318 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.78A	4mxxB-1opkA: 31.6	4mxxB-1opkA: 30.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 78 VAL A 86 ALA A 99 LYS A 101 VAL A 131 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.68A	4mxxB-1s9iA: 5.7	4mxxB-1s9iA: 26.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LYS A 391 VAL A 419 MET A 438 GLY A 441 LEU A 489	None	0.48A	4mxxB-1snxA: 23.7	4mxxB-1snxA: 40.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 595 VAL A 603 ALA A 621 LYS A 623 THR A 670 TYR A 672 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.2A) STI A 3 ( 4.0A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.73A	4mxxB-1t46A: 25.9	4mxxB-1t46A: 35.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LYS A 38 TYR A 86 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) HYM A 400 (-4.7A) None HYM A 400 (-4.5A)	0.84A	4mxxB-1zltA: 14.9	4mxxB-1zltA: 26.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU X 17 VAL X 25 ALA X 37 LYS X 39 VAL X 67 THR X 82 MET X 85 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) None STU X 902 (-4.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A)	0.80A	4mxxB-2dq7X: 35.0	4mxxB-2dq7X: 83.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU X 17 VAL X 25 ALA X 37 VAL X 67 THR X 82 TYR X 84 MET X 85 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-4.1A) STU X 902 (-4.6A) None STU X 902 (-3.5A) STU X 902 (-4.4A)	0.68A	4mxxB-2dq7X: 35.0	4mxxB-2dq7X: 83.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 THR A 338 TYR A 340 MET A 341 GLY A 344 LEU A 393	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None H8H A 534 (-3.1A) H8H A 534 (-4.3A) None H8H A 534 (-3.3A) H8H A 534 (-4.5A)	0.46A	4mxxB-2h8hA: 33.6	4mxxB-2h8hA: 53.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 THR A 338 MET A 341 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.3A) None QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.60A	4mxxB-2hckA: 32.5	4mxxB-2hckA: 50.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 251 VAL A 259 ALA A 271 LYS A 273 VAL A 301 THR A 316 MET A 319 GLY A 322 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) None 1BM A 499 (-3.2A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.61A	4mxxB-2hk5A: 27.1	4mxxB-2hk5A: 66.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 LYS A 271 THR A 315 MET A 318 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) None None GIN A 600 (-4.7A)	0.66A	4mxxB-2hz0A: 30.7	4mxxB-2hz0A: 48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 VAL A 299 THR A 315 MET A 318 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) None None GIN A 600 (-4.7A)	0.74A	4mxxB-2hz0A: 30.7	4mxxB-2hz0A: 48.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 ALA A 271 LYS A 273 THR A 316 TYR A 318 MET A 319 GLY A 322 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.69A	4mxxB-2og8A: 27.8	4mxxB-2og8A: 67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 ALA A 271 VAL A 301 THR A 316 TYR A 318 MET A 319 GLY A 322 LEU A 371	None 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.77A	4mxxB-2og8A: 27.8	4mxxB-2og8A: 67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 ALA A 271 LYS A 273 THR A 316 TYR A 318 MET A 319 LEU A 371	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 4.3A)	0.68A	4mxxB-2og8A: 27.8	4mxxB-2og8A: 67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 ALA A 271 VAL A 301 THR A 316 TYR A 318 MET A 319 LEU A 371	None None 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 4.3A)	0.74A	4mxxB-2og8A: 27.8	4mxxB-2og8A: 67.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 LYS A 616 THR A 663 TYR A 665 GLY A 669 LEU A 785	None	0.84A	4mxxB-2ogvA: 21.0	4mxxB-2ogvA: 34.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 VAL A 647 THR A 663 TYR A 665 GLY A 669 LEU A 785	None	0.75A	4mxxB-2ogvA: 21.0	4mxxB-2ogvA: 34.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	LEU A 25 VAL A 33 ALA A 46 LYS A 48 MET A 106 GLY A 109 LEU A 156	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) ATP A 381 (-3.2A) None None ATP A 381 ( 4.8A)	0.83A	4mxxB-2phkA: 16.4	4mxxB-2phkA: 26.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	8	VAL B 55 ALA B 67 VAL B 98 TYR B 116 MET B 117 GLY B 120 LEU B 171 THR B 181	None	0.75A	4mxxB-2qkwB: 23.5	4mxxB-2qkwB: 30.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 LYS A 653 THR A 699 MET A 702 GLY A 705 LEU A 753	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None None PTR A 701 ( 3.5A) None None	0.61A	4mxxB-2qobA: 26.3	4mxxB-2qobA: 39.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 689 ALA A 705 LYS A 707 TYR A 755 MET A 756 GLY A 759 LEU A 807	None	0.77A	4mxxB-2r2pA: 32.3	4mxxB-2r2pA: 43.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 689 ALA A 705 THR A 753 TYR A 755 MET A 756 GLY A 759 LEU A 807	None	0.36A	4mxxB-2r2pA: 32.3	4mxxB-2r2pA: 43.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 724 VAL A 732 ALA A 749 LYS A 751 VAL A 781 THR A 796 MET A 799 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 ( 4.7A) GW7 A 1 (-4.0A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.77A	4mxxB-2r4bA: 26.5	4mxxB-2r4bA: 39.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 226 VAL A 234 ALA A 247 MET A 304 GLY A 307 LEU A 354 THR A 367	XK9 A1511 (-3.8A) XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A) XK9 A1511 (-3.7A)	0.82A	4mxxB-2xk9A: 20.7	4mxxB-2xk9A: 28.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 LYS A 653 THR A 699 MET A 702 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 (-3.5A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.56A	4mxxB-2xyuA: 29.6	4mxxB-2xyuA: 43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 THR A 699 TYR A 701 MET A 702 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-3.5A) Q9G A1898 (-4.8A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.36A	4mxxB-2xyuA: 29.6	4mxxB-2xyuA: 43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	9	LEU A 253 VAL A 261 ALA A 273 LYS A 275 VAL A 303 THR A 319 MET A 322 GLY A 325 LEU A 374	None	0.58A	4mxxB-2zv7A: 34.9	4mxxB-2zv7A: 64.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ALA A 515 LYS A 517 TYR A 566 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.5A) M33 A1996 ( 4.7A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.68A	4mxxB-3b2tA: 26.2	4mxxB-3b2tA: 36.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 LYS A 222 VAL A 249 THR A 266 MET A 269 GLY A 272 LEU A 321	None	0.69A	4mxxB-3d7uA: 25.8	4mxxB-3d7uA: 41.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 209 ALA A 220 VAL A 249 THR A 266 TYR A 268 MET A 269 GLY A 272 LEU A 321	None	0.53A	4mxxB-3d7uA: 25.8	4mxxB-3d7uA: 41.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 647 ALA A 663 LYS A 665 VAL A 695 MET A 714 GLY A 717 LEU A 765	IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) IHZ A1001 ( 4.5A) IHZ A1001 ( 4.9A) None IHZ A1001 ( 3.9A) IHZ A1001 (-4.6A)	0.56A	4mxxB-3dkoA: 32.0	4mxxB-3dkoA: 41.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 833 VAL A 841 ALA A 859 LYS A 861 VAL A 892 TYR A 911 GLY A 915 LEU A1029	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) 8ST A2001 ( 4.7A) 8ST A2001 (-4.9A) None None	0.95A	4mxxB-3hngA: 29.3	4mxxB-3hngA: 31.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 696 VAL A 704 LYS A 723 VAL A 753 THR A 768 TYR A 770 GLY A 774 LEU A 822	ANP A 1 (-4.4A) ANP A 1 (-3.9A) ANP A 1 (-3.4A) None ANP A 1 ( 4.8A) ANP A 1 (-4.3A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A)	0.55A	4mxxB-3kexA: 27.7	4mxxB-3kexA: 32.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 THR A 713 TYR A 715 MET A 716 GLY A 719 LEU A 767	None None None GOL A 403 (-4.1A) None GOL A 403 (-3.4A) None	0.54A	4mxxB-3kulA: 33.3	4mxxB-3kulA: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lw0	INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1005 VAL A1013 ALA A1031 LYS A1033 VAL A1063 MET A1082 GLY A1085	None None None CCX A 1 ( 3.7A) CCX A 1 (-4.1A) None None	0.80A	4mxxB-3lw0A: 29.2	4mxxB-3lw0A: 36.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 216 ALA A 227 LYS A 229 THR A 277 TYR A 279 GLY A 283 LEU A 337	LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A) LDN A 600 (-4.0A) LDN A 600 (-4.7A) LDN A 600 (-3.3A) LDN A 600 (-4.6A)	0.56A	4mxxB-3my0A: 25.0	4mxxB-3my0A: 27.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	8	LEU A 192 VAL A 200 ALA A 213 LYS A 215 VAL A 247 MET A 266 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None None None AMP A 577 (-4.8A)	0.82A	4mxxB-3nyoA: 21.6	4mxxB-3nyoA: 21.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3oz6	MITOGEN-ACTIVATED PROTEIN KINASE 1, SERINE/THREONINE PROTEIN KINASE (Cryptosporidium parvum)	PF00069 (Pkinase)	7	VAL A 25 ALA A 38 LYS A 40 VAL A 72 TYR A 92 MET A 93 LEU A 141	None	0.78A	4mxxB-3oz6A: 20.5	4mxxB-3oz6A: 23.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 726 VAL A 734 ALA A 751 LYS A 753 MET A 801 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.68A	4mxxB-3pp0A: 29.4	4mxxB-3pp0A: 36.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 726 VAL A 734 ALA A 751 THR A 798 MET A 801 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.61A	4mxxB-3pp0A: 29.4	4mxxB-3pp0A: 36.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	7	VAL A 565 ALA A 576 VAL A 609 THR A 625 TYR A 627 GLY A 631 LEU A 683	STU A 1 (-4.9A) STU A 1 (-3.3A) None STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A)	0.40A	4mxxB-3ppzA: 29.2	4mxxB-3ppzA: 33.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 423 VAL A 431 ALA A 443 LYS A 445 VAL A 473 THR A 489 TYR A 491 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.71A	4mxxB-3sxsA: 31.8	4mxxB-3sxsA: 43.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 423 VAL A 431 ALA A 443 VAL A 473 THR A 489 TYR A 491 GLY A 495 LEU A 543 PHE A 555	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A) PP2 A 1 ( 4.6A)	0.65A	4mxxB-3sxsA: 31.8	4mxxB-3sxsA: 43.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	8	LEU A 295 VAL A 303 ALA A 315 LYS A 317 TYR A 365 MET A 366 GLY A 369 LEU A 423	None	0.83A	4mxxB-3ulzA: 21.9	4mxxB-3ulzA: 28.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 544 VAL A 552 ALA A 570 VAL A 601 TYR A 619 MET A 620 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) None 0F4 A 902 (-4.2A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.70A	4mxxB-3v5qA: 24.9	4mxxB-3v5qA: 35.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 75 VAL A 83 ALA A 96 LYS A 98 VAL A 128 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.70A	4mxxB-3wigA: 16.3	4mxxB-3wigA: 27.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 633 ALA A 649 LYS A 651 THR A 697 MET A 700 GLY A 703 LEU A 751	None	0.62A	4mxxB-3zfxA: 33.0	4mxxB-3zfxA: 42.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 83 VAL A 91 ALA A 104 LYS A 106 TYR A 156 GLY A 160 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) VX6 A 500 (-3.3A) VX6 A 500 (-4.2A) VX6 A 500 (-3.3A) VX6 A 500 (-4.6A)	0.68A	4mxxB-4af3A: 20.0	4mxxB-4af3A: 23.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 560 VAL A 568 ALA A 586 VAL A 617 TYR A 635 MET A 636 GLY A 639 LEU A 699	LTI A1839 ( 4.2A) None LTI A1839 (-3.3A) None LTI A1839 (-4.7A) None LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.69A	4mxxB-4at3A: 23.8	4mxxB-4at3A: 34.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 105 ALA A 121 LYS A 123 THR A 169 MET A 172 GLY A 175 LEU A 223	30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-3.8A) None 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.35A	4mxxB-4aw5A: 29.8	4mxxB-4aw5A: 42.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	VAL A 222 ALA A 233 LYS A 235 THR A 283 TYR A 285 GLY A 289 LEU A 343	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) TAK A1507 (-3.6A) TAK A1507 ( 4.6A) TAK A1507 (-3.5A) TAK A1507 (-4.7A)	0.54A	4mxxB-4c02A: 24.7	4mxxB-4c02A: 27.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 653 LYS A 655 THR A 701 TYR A 703 MET A 704 LEU A 773	None DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.9A) DI1 A1000 (-3.6A) DI1 A1000 (-4.0A) None DI1 A1000 (-4.5A)	0.81A	4mxxB-4ckrA: 29.6	4mxxB-4ckrA: 35.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 663 VAL A 671 ALA A 684 VAL A 721 TYR A 739 GLY A 743 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) None None None AGS A1985 (-4.8A)	0.81A	4mxxB-4crsA: 21.0	4mxxB-4crsA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 515 VAL A 523 ALA A 541 VAL A 572 TYR A 590 MET A 591 GLY A 594 LEU A 656	None	0.51A	4mxxB-4f0iA: 23.7	4mxxB-4f0iA: 34.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.58A	4mxxB-4f4pA: 25.9	4mxxB-4f4pA: 36.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 (-4.8A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A)	0.77A	4mxxB-4fl3A: 28.7	4mxxB-4fl3A: 21.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1122 VAL A1130 ALA A1148 VAL A1180 MET A1199 GLY A1202 LEU A1256	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 ( 4.9A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.55A	4mxxB-4fodA: 30.0	4mxxB-4fodA: 34.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	None	0.57A	4mxxB-4hzsA: 20.9	4mxxB-4hzsA: 37.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.73A	4mxxB-4id7A: 29.8	4mxxB-4id7A: 39.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 TYR A 340 MET A 341 GLY A 344 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A)	0.64A	4mxxB-4k11A: 33.2	4mxxB-4k11A: 94.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 33 VAL A 41 ALA A 54 LYS A 56 VAL A 83 TYR A 101 GLY A 105 LEU A 153	GOL A 404 ( 3.6A) GOL A 404 (-4.5A) GOL A 404 ( 3.1A) GOL A 403 ( 4.6A) GOL A 403 (-4.1A) GOL A 404 ( 4.9A) GOL A 404 (-3.6A) GOL A 403 ( 4.4A)	0.71A	4mxxB-4lg4A: 19.8	4mxxB-4lg4A: 28.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 LYS A 295 VAL A 323 TYR A 340 MET A 341 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.8A) VGG A 601 ( 4.0A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.61A	4mxxB-4lggA: 31.3	4mxxB-4lggA: 98.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	7	VAL A 36 ALA A 49 LYS A 51 THR A 95 MET A 98 GLY A 101 LEU A 150	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) ANP A 401 (-3.8A) None None ANP A 401 (-4.8A)	0.75A	4mxxB-4m69A: 23.0	4mxxB-4m69A: 29.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 VAL A 54 ALA A 67 LYS A 69 VAL A 99 THR A 123 GLY A 128 LEU A 180	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.73A	4mxxB-4o38A: 20.1	4mxxB-4o38A: 27.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 VAL A 603 LYS A 642 THR A 687 TYR A 689 GLY A 693 LEU A 741	2TT A1201 (-4.1A) 2TT A1201 (-4.2A) 2TT A1201 ( 4.6A) None 2TT A1201 (-4.0A) 2TT A1201 (-3.5A) 2TT A1201 (-4.1A)	0.52A	4mxxB-4oliA: 26.3	4mxxB-4oliA: 20.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 627 VAL A 635 ALA A 648 VAL A 685 TYR A 703 GLY A 707 LEU A 753	None	0.81A	4mxxB-4otdA: 21.6	4mxxB-4otdA: 26.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 627 ALA A 644 THR A 692 TYR A 694 MET A 695 GLY A 698 LEU A 746	None	0.40A	4mxxB-4p2kA: 32.3	4mxxB-4p2kA: 44.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 LYS A 644 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-3.4A) P30 A1001 (-4.1A) P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.68A	4mxxB-4rt7A: 25.6	4mxxB-4rt7A: 32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 642 LYS A 644 VAL A 675 TYR A 693 GLY A 697 LEU A 818	None P30 A1001 (-3.4A) P30 A1001 (-3.4A) None P30 A1001 (-4.1A) P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.82A	4mxxB-4rt7A: 25.6	4mxxB-4rt7A: 32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	10	LEU A 14 VAL A 22 ALA A 35 LYS A 37 VAL A 65 THR A 81 TYR A 83 MET A 84 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None ACP A1264 (-4.5A) ACP A1264 ( 4.5A) None ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.56A	4mxxB-4ueuA: 34.1	4mxxB-4ueuA: 62.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 40 VAL A 48 ALA A 61 LYS A 63 VAL A 92 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.77A	4mxxB-4usfA: 17.8	4mxxB-4usfA: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	8	LEU A 193 VAL A 201 ALA A 214 LYS A 216 VAL A 248 MET A 267 GLY A 270 LEU A 321	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) None None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.88A	4mxxB-4wboA: 22.8	4mxxB-4wboA: 20.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	10	LEU B 267 VAL B 275 ALA B 288 LYS B 290 VAL B 318 THR B 334 MET B 337 GLY B 340 LEU B 389 PHE B 401	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) None	0.57A	4mxxB-4xeyB: 32.5	4mxxB-4xeyB: 36.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 408 VAL A 416 ALA A 428 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	None	0.67A	4mxxB-4xi2A: 25.5	4mxxB-4xi2A: 27.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 ALA A 642 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) None P30 A1001 ( 4.4A) P30 A1001 (-3.5A) P30 A1001 (-4.3A)	0.74A	4mxxB-4xufA: 23.3	4mxxB-4xufA: 37.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	10	LEU A 408 VAL A 416 ALA A 428 LYS A 430 VAL A 458 THR A 474 TYR A 476 MET A 477 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None 746 A 702 (-3.7A) 746 A 702 (-4.4A) None 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.73A	4mxxB-4y93A: 31.0	4mxxB-4y93A: 26.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 LYS A 514 TYR A 563 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) 38O A1769 (-4.2A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.82A	4mxxB-5a46A: 30.6	4mxxB-5a46A: 32.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 ALA A 928 LYS A 930 TYR A 980 GLY A 984 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) None 5U3 A1200 (-4.5A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A)	0.68A	4mxxB-5f1zA: 22.3	4mxxB-5f1zA: 34.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 ALA A 756 LYS A 758 TYR A 806 GLY A 810 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) None PTR A 809 (-2.4A) PP1 A2012 (-4.6A)	0.72A	4mxxB-5fm2A: 30.9	4mxxB-5fm2A: 31.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 599 VAL A 607 ALA A 625 LYS A 627 THR A 674 TYR A 676 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.2A) 748 A1001 (-4.0A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.74A	4mxxB-5grnA: 24.3	4mxxB-5grnA: 33.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gz8	PROTEIN O-MANNOSE KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 94 ALA A 105 VAL A 134 THR A 148 TYR A 150 GLY A 154 LEU A 215	None	0.71A	4mxxB-5gz8A: 19.0	4mxxB-5gz8A: 26.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gza	PROTEIN O-MANNOSE KINASE (Danio rerio)	PF07714 (Pkinase_Tyr)	7	VAL A 93 ALA A 104 VAL A 133 THR A 147 TYR A 149 GLY A 153 LEU A 214	ADP A 401 (-4.4A) ADP A 401 (-3.2A) None ADP A 401 ( 4.8A) ADP A 401 ( 4.8A) ADP A 401 ( 4.1A) ADP A 401 (-4.4A)	0.63A	4mxxB-5gzaA: 12.7	4mxxB-5gzaA: 29.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 VAL A 65 ALA A 77 VAL A 109 TYR A 132 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) None IDV A 401 (-3.5A) IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.79A	4mxxB-5i3oA: 22.2	4mxxB-5i3oA: 24.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 718 VAL A 726 ALA A 743 LYS A 745 MET A 793 GLY A 796 LEU A 844 THR A 854	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) None 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A)	0.66A	4mxxB-5j9zA: 31.2	4mxxB-5j9zA: 33.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 284 ALA A 297 LYS A 299 VAL A 328 TYR A 346 GLY A 350 LEU A 396 THR A 406	IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 (-4.5A) None IPW A 601 (-4.5A) IPW A 601 ( 3.8A) IPW A 601 (-4.5A) IPW A 601 (-3.7A)	0.80A	4mxxB-5kbrA: 22.6	4mxxB-5kbrA: 27.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o0y	SERINE/THREONINE-PRO TEIN KINASE TOUSLED-LIKE 2 (Homo sapiens)	no annotation	7	LEU A 468 VAL A 476 ALA A 489 LYS A 491 VAL A 527 TYR A 546 THR A 612	AGS A 801 (-4.1A) AGS A 801 (-4.0A) AGS A 801 (-3.6A) AGS A 801 (-2.8A) None AGS A 801 ( 4.8A) None	0.77A	4mxxB-5o0yA: 14.4	4mxxB-5o0yA: 14.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 106 ALA A 119 LYS A 121 VAL A 153 TYR A 171 MET A 172 GLY A 175 LEU A 221	None	0.85A	4mxxB-5u7qA: 19.6	4mxxB-5u7qA: 23.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	9	LEU A 24 VAL A 32 ALA A 45 LYS A 47 THR A 95 TYR A 97 MET A 98 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.76A	4mxxB-5w5jA: 18.2	4mxxB-5w5jA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	8	LEU A 891 VAL A 899 ALA A 917 LYS A 919 THR A 963 TYR A 965 GLY A 969 LEU A1017	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) ANP A1201 (-3.9A) ANP A1201 (-4.4A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A)	0.74A	4mxxB-5wnoA: 27.9	4mxxB-5wnoA: 14.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	7	VAL A 83 ALA A 95 LYS A 97 VAL A 125 TYR A 143 GLY A 147 LEU A 206	ANP A1000 (-4.1A) ANP A1000 (-3.2A) ANP A1000 (-2.8A) None ANP A1000 (-4.3A) None ANP A1000 (-4.5A)	0.68A	4mxxB-5xd6A: 22.4	4mxxB-5xd6A: 14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	8	LEU A 33 VAL A 41 ALA A 54 LYS A 56 VAL A 83 TYR A 101 GLY A 105 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) None ANP A 501 ( 4.2A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A)	0.62A	4mxxB-6ao5A: 22.5	4mxxB-6ao5A: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 ALA A 906 LYS A 908 VAL A 938 GLY A 962 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) ADP A1201 (-2.8A) None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.85A	4mxxB-6c7yA: 27.6	4mxxB-6c7yA: 16.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	8	LEU A 197 VAL A 205 ALA A 217 LYS A 219 THR A 264 MET A 267 GLY A 270 LEU A 319	FKY A9001 (-4.1A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) None FKY A9001 (-3.0A) None FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.96A	4mxxB-6cz4A: 19.8	4mxxB-6cz4A: 23.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	7	VAL A 200 ALA A 211 VAL A 246 TYR A 264 MET A 265 GLY A 268 LEU A 318	CJT A 502 ( 4.8A) CJT A 502 (-3.4A) None CJT A 502 (-4.5A) CJT A 502 (-4.9A) CJT A 502 ( 4.3A) CJT A 502 (-4.7A)	0.50A	4mxxB-6f3dA: 23.6	4mxxB-6f3dA: 13.57

[["4MXX_B_DB8B601_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",8,"ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.65A","4mxxB-1k2pA:24.9","4mxxB-1k2pA:38.33"],["4MXX_B_DB8B601_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",8,"VAL A 416;ALA A 428;LYS A 430;VAL A 458;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.81A","4mxxB-1k2pA:24.9","4mxxB-1k2pA:38.33"],["4MXX_B_DB8B601_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;LYS A 222;VAL A 249;THR A 266;MET A 269;GLY A 272;LEU A 321","None","0.69A","4mxxB-1k9aA:25.8","4mxxB-1k9aA:30.02"],["4MXX_B_DB8B601_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;VAL A 249;THR A 266;TYR A 268;MET A 269;GLY A 272;LEU A 321","None","0.53A","4mxxB-1k9aA:25.8","4mxxB-1k9aA:30.02"],["4MXX_B_DB8B601_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",7,"VAL A 588;ALA A 606;VAL A 638;TYR A 656;MET A 657;GLY A 660;LEU A 731","None","0.53A","4mxxB-1lufA:32.1","4mxxB-1lufA:32.57"],["4MXX_B_DB8B601_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;VAL A 318;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.78A","4mxxB-1opkA:31.6","4mxxB-1opkA:30.10"],["4MXX_B_DB8B601_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",8,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;VAL A 131;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.68A","4mxxB-1s9iA:5.7","4mxxB-1s9iA:26.87"],["4MXX_B_DB8B601_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LYS A 391;VAL A 419;MET A 438;GLY A 441;LEU A 489","None","0.48A","4mxxB-1snxA:23.7","4mxxB-1snxA:40.07"],["4MXX_B_DB8B601_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",8,"LEU A 595;VAL A 603;ALA A 621;LYS A 623;THR A 670;TYR A 672;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.2A);STI A   3 ( 4.0A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.73A","4mxxB-1t46A:25.9","4mxxB-1t46A:35.11"],["4MXX_B_DB8B601_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;TYR A  86;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);HYM A 400 (-4.7A);None;HYM A 400 (-4.5A)","0.84A","4mxxB-1zltA:14.9","4mxxB-1zltA:26.95"],["4MXX_B_DB8B601_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",9,"LEU X  17;VAL X  25;ALA X  37;LYS X  39;VAL X  67;THR X  82;MET X  85;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);None;STU X 902 (-4.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A)","0.80A","4mxxB-2dq7X:35.0","4mxxB-2dq7X:83.75"],["4MXX_B_DB8B601_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",9,"LEU X  17;VAL X  25;ALA X  37;VAL X  67;THR X  82;TYR X  84;MET X  85;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-4.1A);STU X 902 (-4.6A);None;STU X 902 (-3.5A);STU X 902 (-4.4A)","0.68A","4mxxB-2dq7X:35.0","4mxxB-2dq7X:83.75"],["4MXX_B_DB8B601_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;THR A 338;TYR A 340;MET A 341;GLY A 344;LEU A 393","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;H8H A 534 (-3.1A);H8H A 534 (-4.3A);None;H8H A 534 (-3.3A);H8H A 534 (-4.5A)","0.46A","4mxxB-2h8hA:33.6","4mxxB-2h8hA:53.08"],["4MXX_B_DB8B601_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;THR A 338;MET A 341;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.3A);None;QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.60A","4mxxB-2hckA:32.5","4mxxB-2hckA:50.96"],["4MXX_B_DB8B601_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"LEU A 251;VAL A 259;ALA A 271;LYS A 273;VAL A 301;THR A 316;MET A 319;GLY A 322;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);None;1BM A 499 (-3.2A);None;1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.61A","4mxxB-2hk5A:27.1","4mxxB-2hk5A:66.79"],["4MXX_B_DB8B601_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;LYS A 271;THR A 315;MET A 318;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);None;None;GIN A 600 (-4.7A)","0.66A","4mxxB-2hz0A:30.7","4mxxB-2hz0A:48.19"],["4MXX_B_DB8B601_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;VAL A 299;THR A 315;MET A 318;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);None;None;GIN A 600 (-4.7A)","0.74A","4mxxB-2hz0A:30.7","4mxxB-2hz0A:48.19"],["4MXX_B_DB8B601_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;ALA A 271;LYS A 273;THR A 316;TYR A 318;MET A 319;GLY A 322;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.69A","4mxxB-2og8A:27.8","4mxxB-2og8A:67.17"],["4MXX_B_DB8B601_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;ALA A 271;VAL A 301;THR A 316;TYR A 318;MET A 319;GLY A 322;LEU A 371","None;1N8 A 501 ( 3.4A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.77A","4mxxB-2og8A:27.8","4mxxB-2og8A:67.17"],["4MXX_B_DB8B601_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;ALA A 271;LYS A 273;THR A 316;TYR A 318;MET A 319;LEU A 371","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 4.4A);1N8 A 501 ( 4.3A)","0.68A","4mxxB-2og8A:27.8","4mxxB-2og8A:67.17"],["4MXX_B_DB8B601_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;ALA A 271;VAL A 301;THR A 316;TYR A 318;MET A 319;LEU A 371","None;None;1N8 A 501 ( 3.4A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 4.4A);1N8 A 501 ( 4.3A)","0.74A","4mxxB-2og8A:27.8","4mxxB-2og8A:67.17"],["4MXX_B_DB8B601_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;LYS A 616;THR A 663;TYR A 665;GLY A 669;LEU A 785","None","0.84A","4mxxB-2ogvA:21.0","4mxxB-2ogvA:34.97"],["4MXX_B_DB8B601_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;VAL A 647;THR A 663;TYR A 665;GLY A 669;LEU A 785","None","0.75A","4mxxB-2ogvA:21.0","4mxxB-2ogvA:34.97"],["4MXX_B_DB8B601_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"LEU A  25;VAL A  33;ALA A  46;LYS A  48;MET A 106;GLY A 109;LEU A 156","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);ATP A 381 (-3.2A);None;None;ATP A 381 ( 4.8A)","0.83A","4mxxB-2phkA:16.4","4mxxB-2phkA:26.73"],["4MXX_B_DB8B601_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",8,"VAL B  55;ALA B  67;VAL B  98;TYR B 116;MET B 117;GLY B 120;LEU B 171;THR B 181","None","0.75A","4mxxB-2qkwB:23.5","4mxxB-2qkwB:30.40"],["4MXX_B_DB8B601_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;LYS A 653;THR A 699;MET A 702;GLY A 705;LEU A 753","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;None;PTR A 701 ( 3.5A);None;None","0.61A","4mxxB-2qobA:26.3","4mxxB-2qobA:39.26"],["4MXX_B_DB8B601_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 689;ALA A 705;LYS A 707;TYR A 755;MET A 756;GLY A 759;LEU A 807","None","0.77A","4mxxB-2r2pA:32.3","4mxxB-2r2pA:43.48"],["4MXX_B_DB8B601_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 689;ALA A 705;THR A 753;TYR A 755;MET A 756;GLY A 759;LEU A 807","None","0.36A","4mxxB-2r2pA:32.3","4mxxB-2r2pA:43.48"],["4MXX_B_DB8B601_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",9,"LEU A 724;VAL A 732;ALA A 749;LYS A 751;VAL A 781;THR A 796;MET A 799;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 ( 4.7A);GW7 A   1 (-4.0A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.77A","4mxxB-2r4bA:26.5","4mxxB-2r4bA:39.88"],["4MXX_B_DB8B601_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"LEU A 226;VAL A 234;ALA A 247;MET A 304;GLY A 307;LEU A 354;THR A 367","XK9 A1511 (-3.8A);XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A);XK9 A1511 (-3.7A)","0.82A","4mxxB-2xk9A:20.7","4mxxB-2xk9A:28.82"],["4MXX_B_DB8B601_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;LYS A 653;THR A 699;MET A 702;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 (-3.5A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.56A","4mxxB-2xyuA:29.6","4mxxB-2xyuA:43.43"],["4MXX_B_DB8B601_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;THR A 699;TYR A 701;MET A 702;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-3.5A);Q9G A1898 (-4.8A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.36A","4mxxB-2xyuA:29.6","4mxxB-2xyuA:43.43"],["4MXX_B_DB8B601_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",9,"LEU A 253;VAL A 261;ALA A 273;LYS A 275;VAL A 303;THR A 319;MET A 322;GLY A 325;LEU A 374","None","0.58A","4mxxB-2zv7A:34.9","4mxxB-2zv7A:64.34"],["4MXX_B_DB8B601_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ALA A 515;LYS A 517;TYR A 566;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.5A);M33 A1996 ( 4.7A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.68A","4mxxB-3b2tA:26.2","4mxxB-3b2tA:36.51"],["4MXX_B_DB8B601_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;LYS A 222;VAL A 249;THR A 266;MET A 269;GLY A 272;LEU A 321","None","0.69A","4mxxB-3d7uA:25.8","4mxxB-3d7uA:41.67"],["4MXX_B_DB8B601_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"VAL A 209;ALA A 220;VAL A 249;THR A 266;TYR A 268;MET A 269;GLY A 272;LEU A 321","None","0.53A","4mxxB-3d7uA:25.8","4mxxB-3d7uA:41.67"],["4MXX_B_DB8B601_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 647;ALA A 663;LYS A 665;VAL A 695;MET A 714;GLY A 717;LEU A 765","IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);IHZ A1001 ( 4.5A);IHZ A1001 ( 4.9A);None;IHZ A1001 ( 3.9A);IHZ A1001 (-4.6A)","0.56A","4mxxB-3dkoA:32.0","4mxxB-3dkoA:41.80"],["4MXX_B_DB8B601_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 833;VAL A 841;ALA A 859;LYS A 861;VAL A 892;TYR A 911;GLY A 915;LEU A1029","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);8ST A2001 ( 4.7A);8ST A2001 (-4.9A);None;None","0.95A","4mxxB-3hngA:29.3","4mxxB-3hngA:31.37"],["4MXX_B_DB8B601_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",8,"LEU A 696;VAL A 704;LYS A 723;VAL A 753;THR A 768;TYR A 770;GLY A 774;LEU A 822","ANP A   1 (-4.4A);ANP A   1 (-3.9A);ANP A   1 (-3.4A);None;ANP A   1 ( 4.8A);ANP A   1 (-4.3A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A)","0.55A","4mxxB-3kexA:27.7","4mxxB-3kexA:32.73"],["4MXX_B_DB8B601_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;THR A 713;TYR A 715;MET A 716;GLY A 719;LEU A 767","None;None;None;GOL A 403 (-4.1A);None;GOL A 403 (-3.4A);None","0.54A","4mxxB-3kulA:33.3","4mxxB-3kulA:38.65"],["4MXX_B_DB8B601_1","3lw0","Homo sapiens","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1005;VAL A1013;ALA A1031;LYS A1033;VAL A1063;MET A1082;GLY A1085","None;None;None;CCX A   1 ( 3.7A);CCX A   1 (-4.1A);None;None","0.80A","4mxxB-3lw0A:29.2","4mxxB-3lw0A:36.62"],["4MXX_B_DB8B601_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"VAL A 216;ALA A 227;LYS A 229;THR A 277;TYR A 279;GLY A 283;LEU A 337","LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A);LDN A 600 (-4.0A);LDN A 600 (-4.7A);LDN A 600 (-3.3A);LDN A 600 (-4.6A)","0.56A","4mxxB-3my0A:25.0","4mxxB-3my0A:27.38"],["4MXX_B_DB8B601_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",8,"LEU A 192;VAL A 200;ALA A 213;LYS A 215;VAL A 247;MET A 266;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;None;None;AMP A 577 (-4.8A)","0.82A","4mxxB-3nyoA:21.6","4mxxB-3nyoA:21.50"],["4MXX_B_DB8B601_1","3oz6","Cryptosporidium parvum","MITOGEN-ACTIVATED PROTEIN KINASE 1, SERINE\/THREONINE PROTEIN KINASE","PF00069(Pkinase)",7,"VAL A  25;ALA A  38;LYS A  40;VAL A  72;TYR A  92;MET A  93;LEU A 141","None","0.78A","4mxxB-3oz6A:20.5","4mxxB-3oz6A:23.91"],["4MXX_B_DB8B601_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"LEU A 726;VAL A 734;ALA A 751;LYS A 753;MET A 801;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.68A","4mxxB-3pp0A:29.4","4mxxB-3pp0A:36.72"],["4MXX_B_DB8B601_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"LEU A 726;VAL A 734;ALA A 751;THR A 798;MET A 801;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.61A","4mxxB-3pp0A:29.4","4mxxB-3pp0A:36.72"],["4MXX_B_DB8B601_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",7,"VAL A 565;ALA A 576;VAL A 609;THR A 625;TYR A 627;GLY A 631;LEU A 683","STU A   1 (-4.9A);STU A   1 (-3.3A);None;STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A)","0.40A","4mxxB-3ppzA:29.2","4mxxB-3ppzA:33.12"],["4MXX_B_DB8B601_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",9,"LEU A 423;VAL A 431;ALA A 443;LYS A 445;VAL A 473;THR A 489;TYR A 491;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.71A","4mxxB-3sxsA:31.8","4mxxB-3sxsA:43.01"],["4MXX_B_DB8B601_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",9,"LEU A 423;VAL A 431;ALA A 443;VAL A 473;THR A 489;TYR A 491;GLY A 495;LEU A 543;PHE A 555","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A);PP2 A   1 ( 4.6A)","0.65A","4mxxB-3sxsA:31.8","4mxxB-3sxsA:43.01"],["4MXX_B_DB8B601_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",8,"LEU A 295;VAL A 303;ALA A 315;LYS A 317;TYR A 365;MET A 366;GLY A 369;LEU A 423","None","0.83A","4mxxB-3ulzA:21.9","4mxxB-3ulzA:28.36"],["4MXX_B_DB8B601_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 544;VAL A 552;ALA A 570;VAL A 601;TYR A 619;MET A 620;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);None;0F4 A 902 (-4.2A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.70A","4mxxB-3v5qA:24.9","4mxxB-3v5qA:35.08"],["4MXX_B_DB8B601_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",8,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;VAL A 128;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.70A","4mxxB-3wigA:16.3","4mxxB-3wigA:27.33"],["4MXX_B_DB8B601_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 633;ALA A 649;LYS A 651;THR A 697;MET A 700;GLY A 703;LEU A 751","None","0.62A","4mxxB-3zfxA:33.0","4mxxB-3zfxA:42.14"],["4MXX_B_DB8B601_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",7,"LEU A  83;VAL A  91;ALA A 104;LYS A 106;TYR A 156;GLY A 160;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);VX6 A 500 (-3.3A);VX6 A 500 (-4.2A);VX6 A 500 (-3.3A);VX6 A 500 (-4.6A)","0.68A","4mxxB-4af3A:20.0","4mxxB-4af3A:23.51"],["4MXX_B_DB8B601_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 560;VAL A 568;ALA A 586;VAL A 617;TYR A 635;MET A 636;GLY A 639;LEU A 699","LTI A1839 ( 4.2A);None;LTI A1839 (-3.3A);None;LTI A1839 (-4.7A);None;LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.69A","4mxxB-4at3A:23.8","4mxxB-4at3A:34.20"],["4MXX_B_DB8B601_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"VAL A 105;ALA A 121;LYS A 123;THR A 169;MET A 172;GLY A 175;LEU A 223","30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-3.8A);None;30K A1365 (-3.5A);30K A1365 (-4.5A)","0.35A","4mxxB-4aw5A:29.8","4mxxB-4aw5A:42.09"],["4MXX_B_DB8B601_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"VAL A 222;ALA A 233;LYS A 235;THR A 283;TYR A 285;GLY A 289;LEU A 343","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);TAK A1507 (-3.6A);TAK A1507 ( 4.6A);TAK A1507 (-3.5A);TAK A1507 (-4.7A)","0.54A","4mxxB-4c02A:24.7","4mxxB-4c02A:27.95"],["4MXX_B_DB8B601_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 653;LYS A 655;THR A 701;TYR A 703;MET A 704;LEU A 773","None;DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.9A);DI1 A1000 (-3.6A);DI1 A1000 (-4.0A);None;DI1 A1000 (-4.5A)","0.81A","4mxxB-4ckrA:29.6","4mxxB-4ckrA:35.47"],["4MXX_B_DB8B601_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 663;VAL A 671;ALA A 684;VAL A 721;TYR A 739;GLY A 743;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;None;None;AGS A1985 (-4.8A)","0.81A","4mxxB-4crsA:21.0","4mxxB-4crsA:25.00"],["4MXX_B_DB8B601_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 515;VAL A 523;ALA A 541;VAL A 572;TYR A 590;MET A 591;GLY A 594;LEU A 656","None","0.51A","4mxxB-4f0iA:23.7","4mxxB-4f0iA:34.30"],["4MXX_B_DB8B601_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.58A","4mxxB-4f4pA:25.9","4mxxB-4f4pA:36.68"],["4MXX_B_DB8B601_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 (-4.8A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A)","0.77A","4mxxB-4fl3A:28.7","4mxxB-4fl3A:21.86"],["4MXX_B_DB8B601_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1122;VAL A1130;ALA A1148;VAL A1180;MET A1199;GLY A1202;LEU A1256","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 ( 4.9A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.55A","4mxxB-4fodA:30.0","4mxxB-4fodA:34.12"],["4MXX_B_DB8B601_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","None","0.57A","4mxxB-4hzsA:20.9","4mxxB-4hzsA:37.20"],["4MXX_B_DB8B601_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.73A","4mxxB-4id7A:29.8","4mxxB-4id7A:39.31"],["4MXX_B_DB8B601_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;TYR A 340;MET A 341;GLY A 344;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A)","0.64A","4mxxB-4k11A:33.2","4mxxB-4k11A:94.93"],["4MXX_B_DB8B601_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",8,"LEU A  33;VAL A  41;ALA A  54;LYS A  56;VAL A  83;TYR A 101;GLY A 105;LEU A 153","GOL A 404 ( 3.6A);GOL A 404 (-4.5A);GOL A 404 ( 3.1A);GOL A 403 ( 4.6A);GOL A 403 (-4.1A);GOL A 404 ( 4.9A);GOL A 404 (-3.6A);GOL A 403 ( 4.4A)","0.71A","4mxxB-4lg4A:19.8","4mxxB-4lg4A:28.05"],["4MXX_B_DB8B601_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;VAL A 323;TYR A 340;MET A 341;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.8A);VGG A 601 ( 4.0A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.61A","4mxxB-4lggA:31.3","4mxxB-4lggA:98.52"],["4MXX_B_DB8B601_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"VAL A  36;ALA A  49;LYS A  51;THR A  95;MET A  98;GLY A 101;LEU A 150","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);ANP A 401 (-3.8A);None;None;ANP A 401 (-4.8A)","0.75A","4mxxB-4m69A:23.0","4mxxB-4m69A:29.64"],["4MXX_B_DB8B601_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;VAL A  54;ALA A  67;LYS A  69;VAL A  99;THR A 123;GLY A 128;LEU A 180","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.73A","4mxxB-4o38A:20.1","4mxxB-4o38A:27.25"],["4MXX_B_DB8B601_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 595;VAL A 603;LYS A 642;THR A 687;TYR A 689;GLY A 693;LEU A 741","2TT A1201 (-4.1A);2TT A1201 (-4.2A);2TT A1201 ( 4.6A);None;2TT A1201 (-4.0A);2TT A1201 (-3.5A);2TT A1201 (-4.1A)","0.52A","4mxxB-4oliA:26.3","4mxxB-4oliA:20.34"],["4MXX_B_DB8B601_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 627;VAL A 635;ALA A 648;VAL A 685;TYR A 703;GLY A 707;LEU A 753","None","0.81A","4mxxB-4otdA:21.6","4mxxB-4otdA:26.63"],["4MXX_B_DB8B601_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 627;ALA A 644;THR A 692;TYR A 694;MET A 695;GLY A 698;LEU A 746","None","0.40A","4mxxB-4p2kA:32.3","4mxxB-4p2kA:44.19"],["4MXX_B_DB8B601_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-3.4A);P30 A1001 (-4.1A);P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.68A","4mxxB-4rt7A:25.6","4mxxB-4rt7A:32.17"],["4MXX_B_DB8B601_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 642;LYS A 644;VAL A 675;TYR A 693;GLY A 697;LEU A 818","None;P30 A1001 (-3.4A);P30 A1001 (-3.4A);None;P30 A1001 (-4.1A);P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.82A","4mxxB-4rt7A:25.6","4mxxB-4rt7A:32.17"],["4MXX_B_DB8B601_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",10,"LEU A  14;VAL A  22;ALA A  35;LYS A  37;VAL A  65;THR A  81;TYR A  83;MET A  84;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.5A);None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.56A","4mxxB-4ueuA:34.1","4mxxB-4ueuA:62.24"],["4MXX_B_DB8B601_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  40;VAL A  48;ALA A  61;LYS A  63;VAL A  92;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.77A","4mxxB-4usfA:17.8","4mxxB-4usfA:25.63"],["4MXX_B_DB8B601_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",8,"LEU A 193;VAL A 201;ALA A 214;LYS A 216;VAL A 248;MET A 267;GLY A 270;LEU A 321","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);None;None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.88A","4mxxB-4wboA:22.8","4mxxB-4wboA:20.04"],["4MXX_B_DB8B601_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",10,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;VAL B 318;THR B 334;MET B 337;GLY B 340;LEU B 389;PHE B 401","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);None","0.57A","4mxxB-4xeyB:32.5","4mxxB-4xeyB:36.07"],["4MXX_B_DB8B601_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 408;VAL A 416;ALA A 428;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","None","0.67A","4mxxB-4xi2A:25.5","4mxxB-4xi2A:27.78"],["4MXX_B_DB8B601_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;ALA A 642;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);None;P30 A1001 ( 4.4A);P30 A1001 (-3.5A);P30 A1001 (-4.3A)","0.74A","4mxxB-4xufA:23.3","4mxxB-4xufA:37.69"],["4MXX_B_DB8B601_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",10,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;VAL A 458;THR A 474;TYR A 476;MET A 477;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;746 A 702 (-3.7A);746 A 702 (-4.4A);None;746 A 702 (-3.6A);746 A 702 (-4.4A)","0.73A","4mxxB-4y93A:31.0","4mxxB-4y93A:26.54"],["4MXX_B_DB8B601_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;TYR A 563;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.1A);38O A1769 (-4.2A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.82A","4mxxB-5a46A:30.6","4mxxB-5a46A:32.55"],["4MXX_B_DB8B601_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;ALA A 928;LYS A 930;TYR A 980;GLY A 984;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);None;5U3 A1200 (-4.5A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A)","0.68A","4mxxB-5f1zA:22.3","4mxxB-5f1zA:34.50"],["4MXX_B_DB8B601_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;ALA A 756;LYS A 758;TYR A 806;GLY A 810;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);None;PTR A 809 (-2.4A);PP1 A2012 (-4.6A)","0.72A","4mxxB-5fm2A:30.9","4mxxB-5fm2A:31.59"],["4MXX_B_DB8B601_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",8,"LEU A 599;VAL A 607;ALA A 625;LYS A 627;THR A 674;TYR A 676;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.2A);748 A1001 (-4.0A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.74A","4mxxB-5grnA:24.3","4mxxB-5grnA:33.80"],["4MXX_B_DB8B601_1","5gz8","Mus musculus","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  94;ALA A 105;VAL A 134;THR A 148;TYR A 150;GLY A 154;LEU A 215","None","0.71A","4mxxB-5gz8A:19.0","4mxxB-5gz8A:26.77"],["4MXX_B_DB8B601_1","5gza","Danio rerio","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  93;ALA A 104;VAL A 133;THR A 147;TYR A 149;GLY A 153;LEU A 214","ADP A 401 (-4.4A);ADP A 401 (-3.2A);None;ADP A 401 ( 4.8A);ADP A 401 ( 4.8A);ADP A 401 ( 4.1A);ADP A 401 (-4.4A)","0.63A","4mxxB-5gzaA:12.7","4mxxB-5gzaA:29.13"],["4MXX_B_DB8B601_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;VAL A  65;ALA A  77;VAL A 109;TYR A 132;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);None;IDV A 401 (-3.5A);IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.79A","4mxxB-5i3oA:22.2","4mxxB-5i3oA:24.09"],["4MXX_B_DB8B601_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 718;VAL A 726;ALA A 743;LYS A 745;MET A 793;GLY A 796;LEU A 844;THR A 854","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);None;6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A)","0.66A","4mxxB-5j9zA:31.2","4mxxB-5j9zA:33.23"],["4MXX_B_DB8B601_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",8,"VAL A 284;ALA A 297;LYS A 299;VAL A 328;TYR A 346;GLY A 350;LEU A 396;THR A 406","IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 (-4.5A);None;IPW A 601 (-4.5A);IPW A 601 ( 3.8A);IPW A 601 (-4.5A);IPW A 601 (-3.7A)","0.80A","4mxxB-5kbrA:22.6","4mxxB-5kbrA:27.12"],["4MXX_B_DB8B601_1","5o0y","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TOUSLED-LIKE 2","no annotation",7,"LEU A 468;VAL A 476;ALA A 489;LYS A 491;VAL A 527;TYR A 546;THR A 612","AGS A 801 (-4.1A);AGS A 801 (-4.0A);AGS A 801 (-3.6A);AGS A 801 (-2.8A);None;AGS A 801 ( 4.8A);None","0.77A","4mxxB-5o0yA:14.4","4mxxB-5o0yA:14.74"],["4MXX_B_DB8B601_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",8,"VAL A 106;ALA A 119;LYS A 121;VAL A 153;TYR A 171;MET A 172;GLY A 175;LEU A 221","None","0.85A","4mxxB-5u7qA:19.6","4mxxB-5u7qA:23.81"],["4MXX_B_DB8B601_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",9,"LEU A  24;VAL A  32;ALA A  45;LYS A  47;THR A  95;TYR A  97;MET A  98;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.76A","4mxxB-5w5jA:18.2","4mxxB-5w5jA:28.57"],["4MXX_B_DB8B601_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",8,"LEU A 891;VAL A 899;ALA A 917;LYS A 919;THR A 963;TYR A 965;GLY A 969;LEU A1017","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);ANP A1201 (-3.9A);ANP A1201 (-4.4A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A)","0.74A","4mxxB-5wnoA:27.9","4mxxB-5wnoA:14.14"],["4MXX_B_DB8B601_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",7,"VAL A  83;ALA A  95;LYS A  97;VAL A 125;TYR A 143;GLY A 147;LEU A 206","ANP A1000 (-4.1A);ANP A1000 (-3.2A);ANP A1000 (-2.8A);None;ANP A1000 (-4.3A);None;ANP A1000 (-4.5A)","0.68A","4mxxB-5xd6A:22.4","4mxxB-5xd6A:14.34"],["4MXX_B_DB8B601_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",8,"LEU A  33;VAL A  41;ALA A  54;LYS A  56;VAL A  83;TYR A 101;GLY A 105;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);None;ANP A 501 ( 4.2A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A)","0.62A","4mxxB-6ao5A:22.5","4mxxB-6ao5A:24.94"],["4MXX_B_DB8B601_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;ALA A 906;LYS A 908;VAL A 938;GLY A 962;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);ADP A1201 (-2.8A);None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.85A","4mxxB-6c7yA:27.6","4mxxB-6c7yA:16.24"],["4MXX_B_DB8B601_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",8,"LEU A 197;VAL A 205;ALA A 217;LYS A 219;THR A 264;MET A 267;GLY A 270;LEU A 319","FKY A9001 (-4.1A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);None;FKY A9001 (-3.0A);None;FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.96A","4mxxB-6cz4A:19.8","4mxxB-6cz4A:23.46"],["4MXX_B_DB8B601_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",7,"VAL A 200;ALA A 211;VAL A 246;TYR A 264;MET A 265;GLY A 268;LEU A 318","CJT A 502 ( 4.8A);CJT A 502 (-3.4A);None;CJT A 502 (-4.5A);CJT A 502 (-4.9A);CJT A 502 ( 4.3A);CJT A 502 (-4.7A)","0.50A","4mxxB-6f3dA:23.6","4mxxB-6f3dA:13.57"]]